poisar

Stocks · News reference

Viking Therapeutics Reports Third Quarter 2026 Financial Results and Clinical Trial Progress

Viking Therapeutics announced its third quarter 2026 financial results, reporting a net loss of $183.2 million, while confirming the completion of enrollment for its VK2735 injectable clinical trials.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

VKTX
Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Adria Cimino

    Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.

    Viking Therapeutics is trading 23% below its recent $35 secondary offering price after raising $575 million for phase 3 development of its weight loss drug VK2735. Despite the post-offering stock decline due to dilution concerns, the article argues this presents a buying opportunity for patient investors, as Viking is advancing dual GLP-1/GIP receptor agonist candidates in injectable and oral formats while the weight loss drug market is projected to reach nearly $100 billion by decade's end.

    VKTXLLYNVO
  2. Jeff Siegel

    UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.

    UBS initiated buy coverage of Viking Therapeutics (VKTX) with a $94 price target, implying 250% upside from current levels. The clinical-stage biotech's experimental weight loss drug VK2735 has shown promising results, potentially delivering twice the weight loss of semaglutide and 1.5x that of tirzepatide. Viking is advancing both injectable and oral formulations into phase 3 trials and raised $575 million in September to fund development, though the company faces competition from established players and regulatory risks.

    VKTXLLYNVO